CD24hiCD38hi transitional B cells and CD9 as new biomarker of long-term human lung allograft survival
US11761960B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 27, 2018 |
| Grant date | Sep 19, 2023 |
| Priority date | — |
| Expiry date | Aug 12, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/5052
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to an in vitro method for determining the risk of occurrence of chronic lung graft dysfunction in a human subject comprising: a) measuring the level of CD9+ B cells in a blood sample of the subject, b) comparing the level of CD9+ B cells measured at step a) with one or more reference values of the level of CD9+ B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.